View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest Events4SC 過去の業績この会社の最新の決算報告書はまだ処理中です過去 基準チェック /064SCは17.3%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで13.3%毎年増加している。売上は減少しており、年平均51.6%の割合である。主要情報17.28%収益成長率22.40%EPS成長率Biotechs 業界の成長-14.59%収益成長率-51.56%株主資本利益率n/aネット・マージン-3,800.50%前回の決算情報30 Jun 2025最近の業績更新お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.すべての更新を表示Recent updates分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.収支内訳4SC の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:VSC 収益、費用、利益 ( )EUR Millions日付収益収益G+A経費研究開発費30 Jun 250-82031 Mar 250-82031 Dec 240-82030 Sep 240-82030 Jun 240-82031 Mar 240-82031 Dec 230-82030 Sep 230-82030 Jun 230-82031 Mar 230-113031 Dec 220-144030 Sep 220-194030 Jun 220-235031 Mar 227-165031 Dec 2114-105030 Sep 2115-84530 Jun 2116-74931 Mar 219-1331431 Dec 202-1931830 Sep 201-1931730 Jun 200-1931631 Mar 201-1631531 Dec 192-1431430 Sep 192-1531530 Jun 192-1731631 Mar 193-1731731 Dec 184-1831830 Sep 186-1531730 Jun 187-1231531 Mar 186-1131331 Dec 174-1131130 Jun 172-103931 Mar 172-1141031 Dec 162-1141130 Jun 161-114931 Mar 161-103831 Dec 152-83630 Sep 154-104730 Jun 156-104831 Mar 158-94831 Dec 147-1049質の高い収益: VSCは現在利益が出ていません。利益率の向上: VSCは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: VSCは利益を出していないが、過去 5 年間で年間17.3%の割合で損失を削減してきた。成長の加速: VSCの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: VSCは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 21.7% ) と比較することは困難です。株主資本利益率高いROE: VSCの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/12/18 15:57終値2025/12/16 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋4SC AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。2 アナリスト機関Linda PomeroyEdison Investment ResearchMarcus WieprechtStifel, Equities Research
お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Oct 154SC (FRA:VSC) Is Carrying A Fair Bit Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
お知らせ • Jul 244SC AG, Annual General Meeting, Sep 19, 20254SC AG, Annual General Meeting, Sep 19, 2025, at 11:00 W. Europe Standard Time.
お知らせ • Oct 17+ 3 more updates4SC AG to Report Q3, 2025 Results on Oct 17, 20254SC AG announced that they will report Q3, 2025 results on Oct 17, 2025
New Risk • Sep 22New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 7.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue is less than US$1m (€359k revenue, or US$401k). Minor Risks Shareholders have been diluted in the past year (7.9% increase in shares outstanding). Market cap is less than US$100m (€59.1m market cap, or US$66.0m).
Reported Earnings • Aug 14First half 2024 earnings released: €0.39 loss per share (vs €0.46 loss in 1H 2023)First half 2024 results: €0.39 loss per share (improved from €0.46 loss in 1H 2023). Net loss: €3.96m (loss narrowed 15% from 1H 2023). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
分析記事 • Aug 14Is 4SC (FRA:VSC) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
分析記事 • Apr 03Does 4SC (FRA:VSC) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Reported Earnings • Mar 24Full year 2023 earnings releasedFull year 2023 results: Net loss: €8.24m (loss narrowed 43% from FY 2022).
New Risk • Feb 26New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m (€388k revenue, or US$420k). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€71.8m market cap, or US$77.7m).
お知らせ • Dec 01+ 2 more updates4SC AG to Report Q1, 2024 Results on Apr 18, 20244SC AG announced that they will report Q1, 2024 results on Apr 18, 2024
お知らせ • Nov 28+ 1 more update4SC AG to Report First Half, 2024 Results on Aug 08, 20244SC AG announced that they will report first half, 2024 results on Aug 08, 2024
お知らせ • Sep 254SC AG Presents Positive New Data from the Pivotal RESMAIN Study of Resminostat (Kinselby) At the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting4SC AG announced that renowned dermato-oncology expert and study investigator, Professor Dr. Rudolf Stadler, University Hospital Johannes Wesling, Minden, Germany, presented positive new data from the pivotal RESMAN study of resminostat (Kinselby) at the EORTC Cutaneous Lymphoma Tumour Group Annual Meeting, at the Leiden University Medical Center Amsterdam, The Netherlands, 21-23 September. The presented findings show that maintenance therapy is now clinically proven to postpone disease progression in advanced CTCL which could significantly change clinical practice. In RESMAIN, one of the largest randomized, controlled clinical trials in advanced CTCL, resminostat (Kinselby) treatment has shown a statistically significant improvement in progression free survival of 97.6% compared to placebo, with a risk reduction of 38% in recently announced headline trial results (median PFS: 8.3 months versus 4.2 months; p=0.015; HR: 0.623 (95% CI: 0.424, 0.916). Furthermore, resminostat (Kinselby)'s median time to next treatment (median TTNT) versus placebo showed a significant improvement of 8.8 months compared to 4.2 months; p= 0.002; HR: 0.594 (95% CI: 0.424, 0.916). The side effects of resminostat were mainly mild to moderate, manageable and reversible and the known safety profile of resminostat (Kinselby)was confirmed in the RESMAIN study. Additional analyses established that those treated showed a clinically meaningful improvement in median "total" PFS (defined from start of last prior therapy to disease progression) of 24.3 months, compared to 14.9 months for those in the placebo group. It was also noted that there was a significant delay in the development of new, or worsening of existing, skin tumours.
Reported Earnings • Aug 14First half 2023 earnings released: €0.46 loss per share (vs €1.12 loss in 1H 2022)First half 2023 results: €0.46 loss per share (improved from €1.12 loss in 1H 2022). Net loss: €4.66m (loss narrowed 59% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
お知らせ • Jul 284SC AG to Report Q3, 2023 Results on Oct 19, 20234SC AG announced that they will report Q3, 2023 results on Oct 19, 2023
分析記事 • Apr 28We Think 4SC (FRA:VSC) Needs To Drive Business Growth CarefullyThere's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, 4SC ( FRA:VSC...
Reported Earnings • Mar 19Full year 2022 earnings releasedFull year 2022 results: Net loss: €14.4m (loss widened 41% from FY 2021).
お知らせ • Jan 11European Medicines Agency Accepts 4SC's Eligibility Request for Resminostat in Cutaneous T Cell Lymphoma4SC AG announced that its pre-authorisation eligibility request to the European Medicines Agency (EMA) for resminostat in cutaneous T cell lymphoma had been accepted. During its meeting in December 2022 the CHMP agreed, on the basis of the documentation provided, that resminostat was eligible for submission of an application for a Union Marketing Authorisation according to the centralized procedure as detailed in Regulation (EC) No 726/2004.
お知らせ • Dec 214SC AG to Report First Half, 2023 Results on Aug 10, 20234SC AG announced that they will report first half, 2023 results on Aug 10, 2023
お知らせ • Oct 19+ 1 more update4SC AG to Report Fiscal Year 2022 Results on Mar 30, 20234SC AG announced that they will report fiscal year 2022 results on Mar 30, 2023
Breakeven Date Change • Jan 26No longer forecast to breakevenThe analyst covering 4SC no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of €37.2m in 2022. New forecast suggests the company will make a loss of €6.00m in 2023.
Reported Earnings • Aug 12Second quarter 2021 earnings released: €0.62 loss per share (vs €0.46 loss in 2Q 2020)Second quarter 2021 results: Revenue: -€1.62m (down 3,217% from 2Q 2020). Net loss: €6.30m (loss widened 51% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings.
Reported Earnings • Mar 26Full year 2020 earnings released: €0.41 loss per share (vs €0.41 loss in FY 2019)Full year 2020 results: Net loss: €19.0m (loss widened 36% from FY 2019). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 38% per year, which means it is significantly lagging earnings.
Is New 90 Day High Low • Jan 09New 90-day high: €2.22The company is up 29% from its price of €1.72 on 09 October 2020. The German market is up 9.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 2.0% over the same period.
Is New 90 Day High Low • Dec 18New 90-day low: €1.58The company is down 12% from its price of €1.80 on 18 September 2020. The German market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 9.0% over the same period.
Is New 90 Day High Low • Nov 02New 90-day low: €1.63The company is down 5.0% from its price of €1.72 on 04 August 2020. The German market is down 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 18% over the same period.